Antibody drug conjugate ado trastuzumab emtansine: An updated review / 国际药学研究杂志

ABSTRACT

As a new design strategy of anticancer drugs, antibody-drug conjugates have become a research hotspot in recent years. In 2013, the successful launch of ado trastuzumab emtansine(Kadcyla) provided a new solution for second-line treatment with trastuzumab-resistant HER2-positive advanced breast cancer patients. Based on its excellent clinical performance and HER2‘s overexpressing in many tumors, Roche further attempts to expand it for the therapy of HER2-positive metastatic breast cancer of each line and neoadjuvant for early breast cancer treatment, as well as applications to gastric cancer and non-small cell lung cancer(NSCLC) treatment. In general, results are mixed. Its position as second-line drugs of is further established, but factors such as tumor heterogeneity are still a big challenge. This paper reviews the recent progress in these areas after its launch.